このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Alibaba Health Information Technology マネジメント
マネジメント 基準チェック /24
Alibaba Health Information Technology'sの CEO はDifan Shenで、 Nov2023年に任命され、 の在任期間は 1 年未満です。 の年間総報酬はCN¥ 6.41Mで、 23%給与と77%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.007%を直接所有しており、その価値はHK$ 4.14M 。経営陣と取締役会の平均在任期間はそれぞれ1.8年と1.9年です。
主要情報
Difan Shen
最高経営責任者
CN¥6.4m
報酬総額
| CEO給与比率 | 23.0% |
| CEO在任期間 | less than a year |
| CEOの所有権 | 0.007% |
| 経営陣の平均在職期間 | 1.8yrs |
| 取締役会の平均在任期間 | 1.9yrs |
経営陣の近況
Recent updates
After Leaping 26% Alibaba Health Information Technology Limited (HKG:241) Shares Are Not Flying Under The Radar
Jun 07
Alibaba Health Information Technology's (HKG:241) Solid Earnings Are Supported By Other Strong Factors
Jun 06Risks Still Elevated At These Prices As Alibaba Health Information Technology Limited (HKG:241) Shares Dive 26%
Apr 21Is Now The Time To Look At Buying Alibaba Health Information Technology Limited (HKG:241)?
Apr 16Alibaba Health Information Technology (HKG:241) Might Have The Makings Of A Multi-Bagger
Mar 29Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 36% Undervaluation?
Mar 12With A 25% Price Drop For Alibaba Health Information Technology Limited (HKG:241) You'll Still Get What You Pay For
Jan 17Is Now An Opportune Moment To Examine Alibaba Health Information Technology Limited (HKG:241)?
Jan 07Returns On Capital Are Showing Encouraging Signs At Alibaba Health Information Technology (HKG:241)
Dec 15Shareholders Should Be Pleased With Alibaba Health Information Technology Limited's (HKG:241) Price
Sep 28Alibaba Health Information Technology Limited's (HKG:241) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 02Is Alibaba Health Information Technology Limited (HKG:241) Potentially Undervalued?
Jun 11Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Jun 22Is There An Opportunity With Alibaba Health Information Technology Limited's (HKG:241) 49% Undervaluation?
Dec 01Alibaba Health Information Technology (HKG:241) Is Looking To Continue Growing Its Returns On Capital
Oct 15Estimating The Fair Value Of Alibaba Health Information Technology Limited (HKG:241)
Aug 12Alibaba Health Information Technology (HKG:241) Is Doing The Right Things To Multiply Its Share Price
Jun 25These Analysts Just Made A Huge Downgrade To Their Alibaba Health Information Technology Limited (HKG:241) EPS Forecasts
May 30Earnings Report: Alibaba Health Information Technology Limited Missed Revenue Estimates By 6.8%
May 27The Return Trends At Alibaba Health Information Technology (HKG:241) Look Promising
Mar 23Should You Be Adding Alibaba Health Information Technology (HKG:241) To Your Watchlist Today?
Mar 05How Much Are Alibaba Health Information Technology Limited (HKG:241) Insiders Taking Off The Table?
Feb 15Are Alibaba Health Information Technology's (HKG:241) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Jan 31
If You Had Bought Alibaba Health Information Technology (HKG:241) Stock Three Years Ago, You Could Pocket A 457% Gain Today
Dec 31Has Alibaba Health Information Technology Limited's (HKG:241) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 16Will Alibaba Health Information Technology's (HKG:241) Growth In ROCE Persist?
Dec 01CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | CN¥883m |
| Dec 31 2023 | n/a | n/a | CN¥850m |
| Sep 30 2023 | n/a | n/a | CN¥817m |
| Jun 30 2023 | n/a | n/a | CN¥675m |
| Mar 31 2023 | CN¥6m | CN¥1m | CN¥533m |
| Dec 31 2022 | n/a | n/a | CN¥332m |
| Sep 30 2022 | n/a | n/a | CN¥128m |
| Jun 30 2022 | n/a | n/a | -CN¥69m |
| Mar 31 2022 | CN¥6m | CN¥1m | -CN¥266m |
| Dec 31 2021 | n/a | n/a | -CN¥216m |
| Sep 30 2021 | n/a | n/a | -CN¥167m |
| Jun 30 2021 | n/a | n/a | CN¥91m |
| Mar 31 2021 | n/a | n/a | CN¥349m |
| Dec 31 2020 | n/a | n/a | CN¥313m |
| Sep 30 2020 | n/a | n/a | CN¥278m |
| Jun 30 2020 | n/a | n/a | CN¥136m |
| Mar 31 2020 | CN¥12m | CN¥2m | -CN¥7m |
| Dec 31 2019 | n/a | n/a | -CN¥3m |
| Sep 30 2019 | n/a | n/a | CN¥1m |
| Jun 30 2019 | n/a | n/a | -CN¥40m |
| Mar 31 2019 | CN¥7m | CN¥33k | -CN¥82m |
報酬と市場: Difanの 総報酬 ($USD 883.49K ) は、 Hong Kong市場 ($USD 899.42K ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Difanの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Difan Shen (46 yo)
less than a year
在職期間
CN¥6,406,000
報酬
Mr. Difan Shen serves as Chief Executive Officer of Alibaba Health Information Technology Limited from November 28, 2023 and serves as Executive Director since October 13, 2021. He was Chief Operating Offi...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman of the Board | 4.3yrs | CN¥11.33m | 0.0081% CN¥ 4.5m | |
| CEO & Executive Director | less than a year | CN¥6.41m | 0.0073% CN¥ 4.0m | |
| CFO & Executive Director | 4.2yrs | CN¥3.24m | 0.0046% CN¥ 2.5m | |
| Legal Counsel & Joint Company Secretary | 1.4yrs | データなし | データなし | |
| Chief Marketing Officer | 2.3yrs | データなし | データなし | |
| Chief People Officer | 4.3yrs | データなし | データなし | |
| Financial Controller | no data | データなし | データなし | |
| Chief Legal Advisor & Joint Company Secretary | less than a year | データなし | データなし |
1.8yrs
平均在職期間
46yo
平均年 齢
経験豊富な経営陣: 241の経営陣は 経験豊富 とはみなされません ( 1.8年の平均在職年数)。これは新しいチームを示唆しています。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Executive Chairman of the Board | 4.3yrs | CN¥11.33m | 0.0081% CN¥ 4.5m | |
| CEO & Executive Director | 2.7yrs | CN¥6.41m | 0.0073% CN¥ 4.0m | |
| CFO & Executive Director | 3.7yrs | CN¥3.24m | 0.0046% CN¥ 2.5m | |
| Independent Non-Executive Director | less than a year | データなし | データなし | |
| Independent Non-Executive Director | 5yrs | CN¥330.00k | データなし | |
| Independent Non-Executive Director | less than a year | データなし | データなし | |
| Non-Executive Director | 1.1yrs | データなし | データなし | |
| Non-Executive Director | less than a year | データなし | データなし |
1.9yrs
平均在職期間
48yo
平均年齢
経験豊富なボード: 241の 取締役会 は 経験豊富 ではない ( 1.9年の平均在任期間) ため、新しい取締役会が必要であると考えられます。